Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

P. Čižnár, M. Roderick, H. Schneiderova, M. Jeseňák, G. Kriván, N. Brodszki, S. Jolles, C. Atisso, K. Fielhauer, S. Saeed-Khawaja, B. McCoy, L. Yel

. 2024 ; 20 (1) : 47. [pub] 20240917

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24017798

BACKGROUND: The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). METHODS: This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly. The primary outcome was the number and rate (per infusion) of all noninfectious treatment-related serious and severe adverse events (AEs). RESULTS: In total, 42 patients were enrolled and dosed (median [range] age: 11.5 [3-17] years; 81% male; 23 new starters; 19 pretreated). Overall, 49 related noninfectious, treatment-emergent AEs (TEAEs) were reported in 15 patients; most were mild in severity (87.8%). No treatment-related serious TEAEs were reported. Two TEAEs (infusion site pain and emotional distress) were reported as severe and treatment-related in a single new fSCIG 10% starter. The rate of local TEAEs was lower in pretreated patients (0.1 event/patient-year) versus new starters (1.3 events/patient-year). No patients tested positive for binding anti-rHuPH20 antibodies (titer of ≥ 1:160). CONCLUSIONS: No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. TRIAL REGISTRATION NUMBER (CLINICALTRIALS.GOV): NCT03116347.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017798
003      
CZ-PrNML
005      
20241016081831.0
007      
ta
008      
241008s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13223-024-00904-9 $2 doi
035    __
$a (PubMed)39289739
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Čižnár, Peter $u Department of Paediatrics, Faculty of Medicine, Comenius University Bratislava, National Institute of Children's Diseases, Bratislava, Slovakia
245    10
$a fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study / $c P. Čižnár, M. Roderick, H. Schneiderova, M. Jeseňák, G. Kriván, N. Brodszki, S. Jolles, C. Atisso, K. Fielhauer, S. Saeed-Khawaja, B. McCoy, L. Yel
520    9_
$a BACKGROUND: The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). METHODS: This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly. The primary outcome was the number and rate (per infusion) of all noninfectious treatment-related serious and severe adverse events (AEs). RESULTS: In total, 42 patients were enrolled and dosed (median [range] age: 11.5 [3-17] years; 81% male; 23 new starters; 19 pretreated). Overall, 49 related noninfectious, treatment-emergent AEs (TEAEs) were reported in 15 patients; most were mild in severity (87.8%). No treatment-related serious TEAEs were reported. Two TEAEs (infusion site pain and emotional distress) were reported as severe and treatment-related in a single new fSCIG 10% starter. The rate of local TEAEs was lower in pretreated patients (0.1 event/patient-year) versus new starters (1.3 events/patient-year). No patients tested positive for binding anti-rHuPH20 antibodies (titer of ≥ 1:160). CONCLUSIONS: No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. TRIAL REGISTRATION NUMBER (CLINICALTRIALS.GOV): NCT03116347.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Roderick, Marion $u Department of Paediatric Immunology, Bristol Royal Hospital for Children, Bristol, UK
700    1_
$a Schneiderova, Helen $u Department of Pediatrics, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jeseňák, Miloš $u Centre for Primary Immunodeficiencies, Department of Pediatrics, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia
700    1_
$a Kriván, Gergely $u Department of Pediatric Hematology & Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
700    1_
$a Brodszki, Nicholas $u Department of Pediatric Oncology, Hematology and Immunology, Skåne University Hospital, Lund, Sweden
700    1_
$a Jolles, Stephen $u Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK
700    1_
$a Atisso, Charles $u Takeda Development Center Americas, Inc., Cambridge, MA, USA
700    1_
$a Fielhauer, Katharina $u Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria
700    1_
$a Saeed-Khawaja, Shumyla $u Takeda Development Center Americas, Inc., Cambridge, MA, USA
700    1_
$a McCoy, Barbara $u Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria
700    1_
$a Yel, Leman $u Takeda Development Center Americas, Inc., Cambridge, MA, USA. lyel@uci.edu $u University of California Irvine, Irvine, CA, USA. lyel@uci.edu $1 https://orcid.org/0000000183573186
773    0_
$w MED00205564 $t Allergy, asthma, and clinical immunology $x 1710-1484 $g Roč. 20, č. 1 (2024), s. 47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39289739 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081826 $b ABA008
999    __
$a ok $b bmc $g 2196376 $s 1229749
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 20 $c 1 $d 47 $e 20240917 $i 1710-1484 $m Allergy, asthma, and clinical immunology $n Allergy Asthma Clin Immunol $x MED00205564
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace